Generics Bulletin Explains: US Adalimumab Outlook Brightens At Mid-Point Of 2024
As PBMs Face Increasing Pressure Over Suppressing Uptake For Humira Biosimilars
• By David Wallace
Uptake is beginning to ramp up for US adalimumab biosimilars in 2024 • Source: Shutterstock 
